StradVision스트라드비젼
475040 · KOSDAQ · ₩475040 · 스트라드비젼
What brokers say about StradVision
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
StradVision is still loss-making, with TTM operating losses far larger than its revenue, though it signed a supply contract in October.
StradVision, a Seoul-based maker of AI camera vision software for cars, reported trailing twelve-month revenue of about ₩21.5B against an operating loss of about ₩52.9B as of H1 2026. The company holds ₩85.9B in cash against ₩5.0B of borrowings, and its shares closed at ₩2,275 on 30 October 2026, down 22.9% over one month and 10.8% over three months.
What stands out
- Revenue grew 56.9% in 2025 to about ₩18.1B, but the operating loss widened to about ₩58.6B, an operating margin of -323.6%.
- TTM free cash flow was about -₩43.9B, so the cash balance is being drawn down by operations.
- Filings include a major sales or supply contract on 12 October 2026 and another on 20 August 2026, though the data does not give contract values or counterparties.
- Valuation shows P/B of 1.4 and P/S of 5.7, while P/E is not meaningful because earnings are negative; the data gives no dividend and no fair value estimate.
- Foreign ownership is 0% and short balance is 0.6%; over the last 20 days foreign investors were net sellers of about ₩1.0B while retail investors were net buyers of about ₩0.8B.
What to watch
- The next filed results after the H1 2026 half-year report, to see whether losses narrow relative to revenue.
- Further supply contract filings and whether they disclose revenue or customer details, which the current data does not.
- The stock option grant and the shareholder meeting outcomes, which could affect dilution; the data does not state the size of the grant.
Data as of Oct 30, 2026 · written 4h ago
This is not financial advice.
Also known as: StradVision / 스트라드비젼 / 475040 / KRX:475040
Source: KRX statistical information